NTLA241115C17500
- 0.49
- -0.16-24.62%
Intellia Therapeutics Newsroom
Intellia Therapeutics Is Maintained at Neutral by Goldman Sachs
Intellia Therapeutics' NTLA-2002: Hold Rating Amid Competitive Challenges and Safety Concerns
Intellia Therapeutics: Promising Phase 2 Results and Growth Potential Justify Buy Rating
BofA Securities Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $65
Oppenheimer Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70
Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $60
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $18 to $90
Intellia Therapeutics (NTLA) Gets a Buy From Barclays
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Truist Financial Initiates a Buy Rating on Intellia Therapeutics (NTLA)
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
Buy Rating on Intellia Therapeutics Backed by Promising Phase 1 Study and Upcoming Data Presentation
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
Intellia Therapeutics (NTLA) Receives a Buy From RBC Capital